Study details
Enrolling now
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT IDNCT03223922ClinicalTrials.gov data as of Apr 2026
Target enrollment
24
Study length
about 13 years
Ages
18–100
Locations
2 sites in DC, MD
What this study is about
This trial is testing whether a gentler type of whole brain radiation therapy, which avoids the genu of the corpus callosum, can help preserve cognitive function in people with brain metastases. The goal is to see if preventing radiation damage to this area leads to better outcomes compared to standard whole brain radiation therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive whole brain radiation therapy
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Rate of change in QoL
Procedures
radiation